Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT6003 Injection vs cTACE in Unresectable Hepatocellular Carcinoma
NCT06900543Phase 3Active, not recruiting
- Sponsor
- Chengdu Newray Medical Technology
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 3 trial of yttrium Y 90 carbon microspheres in hepatocellular carcinoma (HCC), sponsored by Chengdu Newray Medical Technology. Started Apr 2025; status: active, not recruiting.
02
Drugs
yttrium Y 90 carbon microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06900543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900543.